Solas Capital Management LLC Purchases New Position in MAIA Biotechnology, Inc. $MAIA

Solas Capital Management LLC purchased a new position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,030,845 shares of the company’s stock, valued at approximately $4,364,000. MAIA Biotechnology accounts for about 2.3% of Solas Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Solas Capital Management LLC owned 4.98% of MAIA Biotechnology at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Centric Wealth Management acquired a new stake in MAIA Biotechnology in the second quarter valued at approximately $1,107,000. BlackRock Inc. acquired a new position in shares of MAIA Biotechnology during the 2nd quarter worth approximately $580,000. Corsair Capital Management L.P. acquired a new position in shares of MAIA Biotechnology during the 1st quarter worth approximately $140,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the 4th quarter valued at approximately $120,000. Finally, PVG Asset Management Corp purchased a new position in shares of MAIA Biotechnology during the 1st quarter valued at approximately $46,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

Insider Activity

In related news, Director Stan Smith bought 75,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was acquired at an average price of $1.34 per share, with a total value of $100,500.00. Following the completion of the purchase, the director directly owned 1,519,178 shares of the company’s stock, valued at approximately $2,035,698.52. This trade represents a 5.19% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Vlad Vitoc bought 72,700 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were bought at an average cost of $1.39 per share, with a total value of $101,053.00. Following the purchase, the chief executive officer directly owned 976,121 shares of the company’s stock, valued at approximately $1,356,808.19. This represents a 8.05% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 161,599 shares of company stock worth $220,535. Company insiders own 19.81% of the company’s stock.

MAIA Biotechnology Stock Performance

MAIA Biotechnology stock opened at $1.35 on Tuesday. The company’s fifty day moving average price is $1.37 and its 200 day moving average price is $1.46. MAIA Biotechnology, Inc. has a 1 year low of $0.87 and a 1 year high of $3.19. The stock has a market capitalization of $82.12 million, a P/E ratio of -2.18 and a beta of 0.24.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Sell-side analysts predict that MAIA Biotechnology, Inc. will post -0.54 EPS for the current year.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.